Allos (ALTH) Reports Publication of Encouraging FOLOTYN Data
Tweet
Share
E-mailGet Alerts ALTH Hot Sheet
Join SI Premium – FREE
Allos Therapeutics, Inc. (Nasdaq: ALTH), reports strong data for FOLOTYN.
A pivotal PROPEL trial suggested that treatment with single-agent FOLOTYN (pralatrexate injection) may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
The analysis assessed those patients enrolled in the PROPEL trial who had received two or more lines of therapy prior to enrolling in the study and receiving FOLOTYN.
PROPEL enrolled 115 patients, 109 of whom were considered evaluable for efficacy according to the trial protocol. Study endpoints included overall response rate – defined as complete response, unconfirmed complete response, and partial response – as well as duration of response, progression-free survival, and overall survival. Patients enrolled in PROPEL had a median of three prior systemic therapies.
A pivotal PROPEL trial suggested that treatment with single-agent FOLOTYN (pralatrexate injection) may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
The analysis assessed those patients enrolled in the PROPEL trial who had received two or more lines of therapy prior to enrolling in the study and receiving FOLOTYN.
PROPEL enrolled 115 patients, 109 of whom were considered evaluable for efficacy according to the trial protocol. Study endpoints included overall response rate – defined as complete response, unconfirmed complete response, and partial response – as well as duration of response, progression-free survival, and overall survival. Patients enrolled in PROPEL had a median of three prior systemic therapies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
